H2020Individual fellowship2020–2022

AmyloAge · balancing proteostasis and metabolism in age-related muscular degeneration

Horizon 2020 — Marie Skłodowska-Curie Actions

Duration
2020-09-01 → 2022-08-31
EU contribution
€203,149
Participants
1
Scheme
MSCA-IF

Lines connect the coordinator with its partners.

Results in brief

AmyloAge: balancing proteostasis and metabolism in age-related muscular degeneration

The combination of obesity with low muscle mass, termed sarcopenic obesity, is a huge risk factor for disease and early death. Yet, we do not know much yet about the effects of diet, sex and age on sarcopenic obesity. Project AmyloAge has three objectives (O): O1: To identify and quantify the variations in genes and proteins related to protein aggregation in the muscle I am preparing a publication in which I demonstrate that aggregation-prone proteins other than amyloid-β also accumulate with calory-rich diets. Moreover, increased amounts of aggregation-prone proteins are correlated with perturbed mitochondria. Chaperones in the α-crystallin/Hsp20 family correlate negatively with these aggregation-prone proteins. Moreover, humans with higher expression of α-crystallins seem to have increased muscle mass and increased basal metabolism. O2: To uncover the impact of mitochondrial activity on muscle proteostasis I made use of the worm RIAILS reference genetic population. Here, the project identified new genetic determinants of mitochondrial stress triggered by the mitochondrial ribosome inhibitor doxycycline. From every worm line, we assessed molecular and phenotypic traits. Short-lived strains benefit more from doxycycline, and the longer the worms took to develop and lay eggs, the longer they lived. I collaborated with other lab members to genetically map and validate new compounds that trigger beneficial mitochondrial stresses. I next investigated whether the mitochondrial response to diet is different between male and female mice. I found that the ratios of certain important mitochondrial complexes are perturbed when mice are fed a high-fat diet. Moreover, some of these perturbations are different between male and female mice. The project furthermore revealed that exercising results in the production of an important inflammation-stimulating protein in the brain which causes the muscles to burn more fat. O3: To uncover the genetic and metabolic pathways that drive muscle aging Through a collaboration with a geology research group in France, I was able to assess the metal contents (“metallome”) in mice at different ages. The metallome shows consistent changes with aging. The project reveals for example that iron concentration and copper isotope composition are related to age-related muscle metabolism. The project further suggests that muscle protein aggregation diseases are worst displays of a natural variation in protein aggregation during aging. AmyloAge identifies an important class of fatty acids, the sphingolipids, as key regulators of disease severity in Duchenne muscular dystrophy. Sphingolipids accumulate in the muscles of mouse models for Duchenne muscular dystrophy. Myriocin, a potent inhibitor of sphingolipid synthesis, strongly reduces sphingolipids, and improves the molecular signature, as well as the functional performance in our mouse model.

Data: CORDIS, © European Union

Project objective

After the age of 30, our muscle strength declines by ~14% per decade. In up to 40% of the elderly, this decline culminates in sarcopenia (SP), critically low muscle mass, causing impaired mobility and longer hospitalizations. Muscle decline rates vary greatly between individuals due to genetic and environmental factors. Yet, our lack of insight into these factors impedes developing effective measures against SP. SP is clinically similar to inclusion body myositis (IBM), the most common myopathy in the elderly, and their molecular phenotypes are very similar. Preliminary data from my host lab, the Laboratory of Integrative Systems Physiology (LISP), show that high-fat diet induces amyloid-containing aggregates in the muscles of aging mice. Such aggregates are hallmarks of muscle proteinopathies such as IBM. Hence, these diseases may be the pathological extremes of natural protein aggregation in the muscle. LISP recently described the protective, therapeutic role of activating mitochondrial stress responses in aggregation diseases. Activating these pathways prevents aggregate formation in cells, worms and transgenic Alzheimer’s mice. I thus hypothesize that mitochondrial dysfunction worsens the pathology of muscle aggregation diseases and SP. My project AmyloAge will explore natural aging in muscle in large, genetically diverse populations of worms, mice and humans. I will use my expertise in proteomics to study the evolution of muscle protein composition and find the genetic determinants associated with unhealthy protein aggregation and muscle decline. With my expertise in biostatistics, I will build an analysis pipeline to find the genes and molecular pathways responsible for protein aggregation and metabolic dysfunction in the muscle. AmyloAge will increase our knowledge of the molecular and physiological variability in muscle aging. This will lay the groundwork for preventive interventions against SP and protein aggregation diseases like IBM.

Original text from CORDIS.

Participants

  • ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE · LausanneCoordinatorSwitzerland

Links

Data: CORDIS, © European Union